论文部分内容阅读
为了探讨肝炎肝硬化（ＨＣ）患者血清可溶性白介素６受体（ｓＩＬ－６Ｒ）和可溶性ｇｐ１３０（ｓｇｐ１３０）含量的变化及其临床意义，运用酶联免疫吸附法检测了３４例ＨＣ患者血清ｓＩＬ－６Ｒ和ｓｇｐｌ３０含量。结果表明：①活动性和静止性ＨＣ患者血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平均高于正常对照（Ｐ＜０．０１），ｓＩＬ－６Ｒ／ｓｇｐ１３０比值ＨＣ患者低于正常人，活动性ＨＣ患者低于静止性ＨＣ患者（Ｐ＜０．０１）；②血清ｓＩＬ－６Ｒ和ｓｇｐ１３０水平之间呈正相关（ｒ＝０．４１７，Ｐ＜０．０５），ｓＩＬ－６Ｒ、ｓｇｐｌ３０水平与血清Ｂｉｌ－Ｔ水平间亦呈正相关（分别为ｒ＝０．４７４，ｒ＝０．４８２，Ｐ＜０．０１），而与血清ＡＬＴ水平无明显相关性（分别为ｒ＝０．１９３，ｒ＝０．１５２，Ｐ＞０．０５）。提示：血清ｓＩＬ－６Ｒ、ｓｇｐ１３０与ＨＣ的病情演变有关
In order to investigate the changes of serum soluble interleukin 6 receptor (sIL-6R) and soluble gp130 (sgp130) in patients with hepatitis cirrhosis (HC) and its clinical significance, ELISA was used to detect the serum levels of sIL-6R And sgpl30 content. The results showed that: (1) The levels of serum sIL-6R and sgp130 in active and inactive HC patients were significantly higher than those in normal controls (P <0.01). The sIL-6R / sgp130 ratios in HC patients were lower than those in normal subjects and those in active HC patients were lower than There was a positive correlation between serum sIL-6R and sgp130 levels (r = 0.417, P <0.05). The levels of sIL-6R and sgpl30 were positively correlated with serum Bil-T level (R = 0.474, r = 0.482, P <0.01, respectively) but no significant correlation with serum ALT levels (r = 0.193, r = 0.152, P> 0.05). Tip: Serum sIL-6R, sgp130 HC and the evolution of the disease